Malignant and borderline phyllodes tumor of breast treated with a multi-modality approach in a tertiary cancer care centre in North India

Abstract

Background: Phyllodes tumor (PT) of the breast can be categorized into benign, borderline and malignant subgroups depending on various histopathological factors. Although malignant PTs may be indolent and controlled by local excision, they frequently show local and distant relapses. Literature reveals local recurrence to be the predominant pattern of failure and thus emphasizes the importance of adjuvant radiation in these tumors. The role of systemic chemotherapy has remained doubtful. Materials and Methods: We have analyzed details of all patients of PT (n = 33) treated with adjuvant multi-modality approach in our institute since 1994–2009. The demographic data, treatment details, recurrence patterns and salvage treatment options were documented. Results: All patients received adjuvant radiation. Seven patients received adjuvant chemotherapy. The mean survival of the entire cohort was 150.618 months. There was a trend for better overall survival with borderline grade (193.6 vs. 160.2 months; P = 0.08, log rank). The disease free survival (DFS) favored borderline grade (193.6 months vs. 82.9 months for high grade; P = 0.02, log rank). The DFS was significantly better in tumors having negative margins on postoperative histopathological examination (DFS rate at 5 years being 100% vs. 69.2% for positive or close margins; P = 0.015). The mode of surgery did not have any impact on survival. Conclusion: Adjuvant Radiation should be discussed taking into account surgical margins, size and various pathological factors of the primary. Adjuvant radiation may be utilized in high risk patients to enhance loco-regional control. Systemic chemotherapy is an option, worth exploring, in cases of systemic failure.

Key words

Adjuvant radiation - borderline - malignant - phyllodes tumors - systemic chemotherapy

Publikationsverlauf

Artikel online veröffentlicht:
30. Dezember 2020

• References

• 1 Reinfuss M, Mitus J, Duda K, Stelmach A, Rys J, Smolak K. The treatment and prognosis of patients with phyllodes tumor of the breast: An analysis of 170 cases. Cancer 1996;77:910 6.
• 2 Fou A, Schnabel FR, Hamele Bena D, Wei XJ, Cheng B, El Tamer M, et al. Long term outcomes of malignant phyllodes tumors patients: An institutional experience. Am J Surg 2006;192:492 5.
• 3 Norris HJ, Taylor HB. Relationship of histologic features to behavior of cystosarcoma phyllodes. Analysis of ninety four cases. Cancer 1967;20:2090 9.
• 4 Khosravi Shahi P. Management of non metastatic phyllodes tumors of the breast: Review of the literature. Surg Oncol 2011;20:e143 8.
• 5 Pezner RD, Schultheiss TE, Paz IB. Malignant phyllodes tumor of the breast: Local control rates with surgery alone. Int J Radiat Oncol Biol Phys 2008;71:710 3.
• 6 Ben Hassouna J, Damak T, Gamoudi A, Chargui R, Khomsi F, Mahjoub S, et al. Phyllodes tumors of the breast: A case series of 106 patients. Am J Surg 2006;192:141 7.
• 7 Barth RJ Jr, Wells WA, Mitchell SE, Cole BF. A prospective, multi institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol 2009;16:2288 94.
• 8 Belkacémi Y, Bousquet G, Marsiglia H, Ray Coquard I, Magné N, Malard Y, et al. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys 2008;70:492 500.
• 9 Kapiris I, Nasiri N, A’Hern R, Healy V, Gui GP. Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high grade malignant phyllodes tumours of the breast. Eur J Surg Oncol 2001;27:723 30.
• 10 West TL, Weiland LH, Clagett OT. Cystosarcoma phyllodes. Ann Surg 1971;173:520 8.